Guillain-Barre syndrome
disease diseaseOn this page
Also known as acute autoimmune peripheral neuropathyacute immune-mediated polyneuropathyacute inflammatory demyelinating polyneuropathyacute inflammatory neuropathyGBSGuillain Barre syndromeGuillain Barré syndromeGuillain-Barre-Strohl syndromeGuillain-Barré syndromeGuillain-Barré-Strohl syndromeLandry's ascending paralysisLandry-Guillain-Barre-Strohl syndromepost-infectious polyneuritispost-infective polyneuritispostinfectious polyneuritis
Summary
Guillain-Barre syndrome (MONDO:0016218) is a disease (an umbrella term covering 11 Mondo subtypes) and 79 clinical trials. Top therapeutic interventions include efgartigimod alfa, crovalimab, and dalfampridine. A subtype of autoimmune disorder of peripheral nervous system — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
- Umbrella term: 11 Mondo subtypes
- Clinical trials: 79
Clinical features
Epidemiology
Prevalence records
7 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | 1-9 / 100 000 | 1.45 | Worldwide | Validated |
| Point prevalence | 1-9 / 100 000 | 3.5 | Europe | Validated |
| Annual incidence | 1-9 / 100 000 | 1.72 | United States | Validated |
| Annual incidence | 1-9 / 100 000 | 2.42 | France | Validated |
| Point prevalence | 1-5 / 10 000 | 25 | Denmark | Validated |
| Point prevalence | 1-5 / 10 000 | 12 | Egypt | Validated |
| Annual incidence | 1-9 / 100 000 | 1.4 | Europe | Not yet validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | Guillain-Barre syndrome |
| Mondo ID | MONDO:0016218 |
| EFO | EFO:0007292 |
| MeSH | D020275 |
| Orphanet | 2103 |
| DOID | DOID:12842 |
| ICD-10-CM | G61.0 |
| NCIT | C116345 |
| SNOMED CT | 40956001 |
| UMLS | C0018378 |
| MedGen | 5399 |
| GARD | 0006554 |
| MedDRA | 10018767 |
| Is cancer (heuristic) | no |
Also known as: acute autoimmune peripheral neuropathy · acute immune-mediated polyneuropathy · acute inflammatory demyelinating polyneuropathy · acute inflammatory neuropathy · GBS · Guillain Barre syndrome · Guillain Barré syndrome · Guillain-Barre-Strohl syndrome · Guillain-Barré syndrome · Guillain-Barré-Strohl syndrome · Landry’s ascending paralysis · Landry-Guillain-Barre-Strohl syndrome · post-infectious polyneuritis · post-infective polyneuritis · postinfectious polyneuritis
Data availability: 6 cell lines.
Disease family
This is a subtype of autoimmune disorder of peripheral nervous system. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › nervous system disorder › autoimmune disorder of the nervous system › autoimmune disorder of peripheral nervous system › Guillain-Barre syndrome
Related subtypes (3): autoimmune neuropathy, myasthenia gravis, autoimmune optic neuritis
Subtypes (11): Guillain-Barre syndrome, familial, pharyngeal-cervical-brachial variant of Guillain-Barre syndrome, paraparetic variant of Guillain-Barre syndrome, acute pure sensory neuropathy, autoimmune autonomic ganglionopathy, acute sensory ataxic neuropathy, facial diplegia with paresthesias, acute inflammatory demyelinating polyradiculoneuropathy, acute motor and sensory axonal neuropathy, acute motor axonal neuropathy, polyneuropathy, inflammatory demyelinating, chronic
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated or in trials for this disease
1 approved drug — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Status |
|---|---|
| Human Immunoglobulin G | Approved (phase 4) |
6 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.
| Drug | Highest phase |
|---|---|
| ANX-005 | Phase 3 |
| Crovalimab | Phase 3 |
| Eculizumab | Phase 3 |
| Dalfampridine | Phase 2 |
| Efgartigimod Alfa | Phase 2 |
| Imlifidase | Phase 2 |
Clinical trials & evidence
Clinical trials
Clinical trials: 79.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 60 |
| PHASE3 | 6 |
| PHASE2 | 5 |
| PHASE4 | 2 |
| PHASE2/PHASE3 | 2 |
| PHASE1 | 2 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06620198 | PHASE4 | ACTIVE_NOT_RECRUITING | Upper Limb Robot-Assisted Therapy in Patients with Guillain-Barré Syndrome |
| NCT06041451 | PHASE4 | UNKNOWN | Early and Late Prognosis in Patients With Guillain-Barre Syndrome |
| NCT06885762 | PHASE2/PHASE3 | NOT_YET_RECRUITING | Efgartigimod for the Treatment of Guillain-Barré Syndrome |
| NCT07020819 | PHASE3 | RECRUITING | An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) |
| NCT02221271 | PHASE3 | COMPLETED | Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome |
| NCT02342184 | PHASE3 | COMPLETED | Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome |
| NCT04701164 | PHASE3 | COMPLETED | Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome |
| NCT04752566 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome |
| NCT05104762 | PHASE2/PHASE3 | COMPLETED | IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome Patients |
| NCT05494619 | PHASE3 | WITHDRAWN | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS) |
| NCT00056810 | PHASE2 | COMPLETED | Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine |
| NCT00167622 | PHASE2 | COMPLETED | Early Mechanical Ventilation for Guillain Barré Syndrome |
| NCT02780570 | PHASE2 | COMPLETED | Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome (GBS) Patients |
| NCT03943589 | PHASE2 | COMPLETED | A Study of Imlifidase in Patients With Guillain-Barré Syndrome |
| NCT04846010 | PHASE1/PHASE2 | UNKNOWN | Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 |
| NCT05701189 | PHASE2 | WITHDRAWN | Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome |
| NCT03773328 | PHASE1 | WITHDRAWN | A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS) |
| NCT04035135 | PHASE1 | COMPLETED | A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS) |
| NCT06334796 | EARLY_PHASE1 | COMPLETED | Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology |
| NCT04829526 | Not specified | RECRUITING | Firm Observational Clinical Unicenter Study on Guillain Barré Syndrome |
| NCT04871035 | Not specified | RECRUITING | Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS) |
| NCT05114941 | Not specified | NOT_YET_RECRUITING | Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome |
| NCT05461898 | Not specified | RECRUITING | RehabGBs: Rehabilitation in People With Guillain-Barré Syndrome |
| NCT06167239 | Not specified | RECRUITING | Ventilator Trigger Sensitivity Adjustment Versus Threshold Inspiratory Muscle Training on Arterial Blood Gases |
| NCT06502015 | Not specified | RECRUITING | Biomarkers in Autoimmune Disease of Nervous System |
| NCT06605612 | Not specified | ENROLLING_BY_INVITATION | Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders |
| NCT06612242 | Not specified | RECRUITING | Early vs. Late Tracheostomy in Patients With Guillain -Barre Syndrome |
| NCT06615622 | Not specified | RECRUITING | Our Study Aims to Determine if Nerve Alterations in Acute GBS and CIDP Detectable by Ultrasound Match Electrodiagnostic Findings and if This Method Aids Early Diagnosis, Predict Their Outcomes and Differentiate Between Axonal and Demyelinating Subtypes. |
| NCT06740656 | Not specified | NOT_YET_RECRUITING | Neuromuscular Complications of MEK Inhibitors: a French Case Series and a Systematic Review of the Literature |
| NCT06822231 | Not specified | RECRUITING | High-Tech Rehabilitation Pathway for Acute Adult Neuromuscular Diseases - Fit4MedRob-Acute MND Project |
| NCT06940908 | Not specified | RECRUITING | Living With Guillain-Barré Syndrome as Children. |
| NCT06996509 | Not specified | RECRUITING | Noninvasive Support for Acute Respiratory Failure in Guillain-Barré Syndrome |
| NCT07072676 | Not specified | ENROLLING_BY_INVITATION | The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period. |
| NCT07121985 | Not specified | NOT_YET_RECRUITING | Multispectral Optoacoustic Imaging for the Detection of Inflammation and Damage of Peripheral Nerves in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy |
| NCT00004833 | Not specified | TERMINATED | Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre Syndrome |
| NCT00173199 | Not specified | UNKNOWN | The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin Innervation |
| NCT00575653 | Not specified | COMPLETED | Safety Study of GBS Following Menactra Meningococcal Vaccination |
| NCT01005524 | Not specified | COMPLETED | Brain Computer Interface for Communication in ICU: a Feasibility Study |
| NCT01306578 | Not specified | COMPLETED | Intravenous Immunoglobulin (IVIG) Versus Plasma Exchange (PE) for Ventilated Children With Guillain Barre Syndrome (GBS) |
| NCT01370200 | Not specified | COMPLETED | Regional Citrate Anticoagulation in Plasma Exchange Treatment |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| EFGARTIGIMOD ALFA | 4 | 2 |
| CROVALIMAB | 4 | 1 |
| DALFAMPRIDINE | 4 | 1 |
| ECULIZUMAB | 4 | 1 |
| HUMAN IMMUNOGLOBULIN G | 4 | 1 |
| IMLIFIDASE | 4 | 1 |
| ANX-005 | 3 | 2 |
| FIBRINOGEN, HUMAN | 3 | 1 |